HLB Pharmaceutical Co. Ltd (047920) — Cash Flow-to-Debt Ratio
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩1.86 Billion could theoretically repay 0% of its total liabilities (₩46.98 Billion) in one year. See HLB Pharmaceutical Co. Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
HLB Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for HLB Pharmaceutical Co. Ltd across 11 annual periods. For the full cash flow conversion analysis, see HLB Pharmaceutical Co. Ltd cash flow conversion.
Annual Cash Flow-to-Debt Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for HLB Pharmaceutical Co. Ltd. Check how high is HLB Pharmaceutical Co. Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.16x | ₩6.84 Billion | ₩41.53 Billion | ▲ +147.8% |
| 2023 | -0.34x | ₩-18.32 Billion | ₩53.20 Billion | ▼ -601.0% |
| 2022 | -0.05x | ₩-2.76 Billion | ₩56.25 Billion | ▼ -83.1% |
| 2021 | -0.03x | ₩-1.32 Billion | ₩49.25 Billion | ▼ -344.3% |
| 2020 | -0.01x | ₩-403.36 Million | ₩66.80 Billion | ▼ -113.0% |
| 2019 | 0.05x | ₩1.35 Billion | ₩29.04 Billion | ▲ +150.9% |
| 2018 | -0.09x | ₩-1.78 Billion | ₩19.42 Billion | ▼ -168.9% |
| 2017 | -0.03x | ₩-784.30 Million | ₩23.04 Billion | ▼ -256.8% |
| 2016 | -0.01x | ₩-213.11 Million | ₩22.34 Billion | ▲ +84.3% |
| 2015 | -0.06x | ₩-769.59 Million | ₩12.67 Billion | ▼ -165.4% |
| 2014 | 0.09x | ₩1.54 Billion | ₩16.62 Billion | — |